Compare AZZ & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | AMRX |
|---|---|---|
| Founded | 1956 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 1994 | 2018 |
| Metric | AZZ | AMRX |
|---|---|---|
| Price | $137.86 | $12.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $141.80 | $15.60 |
| AVG Volume (30 Days) | 160.8K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ 486.59 | 157.89 |
| EPS | ★ 10.50 | 0.22 |
| Revenue | ★ $1,061,817,000.00 | N/A |
| Revenue This Year | $7.03 | $4.48 |
| Revenue Next Year | $4.25 | $7.13 |
| P/E Ratio | ★ $13.42 | $57.57 |
| Revenue Growth | ★ 14.53 | N/A |
| 52 Week Low | $86.06 | $7.02 |
| 52 Week High | $147.32 | $15.42 |
| Indicator | AZZ | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 49.87 |
| Support Level | $131.60 | $12.50 |
| Resistance Level | $140.60 | $12.85 |
| Average True Range (ATR) | 4.75 | 0.49 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 40.96 | 30.56 |
AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.